TAF-test: a tumor diagnosis device in oncologic urology

Area of Science:

• Oncology
• Immunology
• Virology

Background:

• Herpes simplex virus tumor-associated antigens (HSV-TAA) are implicated in certain cancers.
• Accurate diagnostic and monitoring tools for these cancers are crucial.

Purpose of the Study:

• To evaluate a screening test for antibodies to HSV-TAA in patients with urinary bladder and prostatic carcinoma.
• To assess the test's utility in monitoring treatment response.

Main Methods:

• A screening test for HSV-TAA antibodies was performed on sera from 26 urinary bladder carcinoma patients and 30 prostatic carcinoma patients.
• Control groups included patients with benign prostatic hypertrophy and renal pelvis/ureter neoplasias.
• Antibody levels were monitored before, during, and after surgical treatment.

Main Results:

• Positive results for HSV-TAA antibodies were observed in 50% of urinary bladder cancer sera and 60% of prostatic carcinoma sera.
• Control sera from benign prostatic hypertrophy and renal pelvis/ureter neoplasias were predominantly negative.
• One positive control patient became negative after surgery, indicating treatment impact.

Conclusions:

• The HSV-TAA antibody test demonstrates potential as a meaningful tool for monitoring antibody levels in cancer patients.
• The test may aid in evaluating the presence of metastases or the success of therapeutic interventions.